{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:51:19Z","timestamp":1792533079223,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016344","name":"Ministry of Health and Population","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016344","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The empirical use of linezolid as a first-line agent for Methicillin-Resistant Staphylococcus Aureus (MRSA) without a clear indication is of high concern. This study aims to investigate the impact of an Antimicrobial Stewardship Program (ASP) on linezolid consumption and susceptibility in Intensive Care Unit (ICU). In particular, for patients with MRSA infection, ensuring optimized anti-MRSA therapy to align with international\/national guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective cohort study was conducted from 01.10.2022 to 31.03.2024 in the ICU of Al-Gomhoreya General Hospital, Alexandria, Egypt. This study included a total of 168 ICU adult patients; older than 18 years old and whom were prescribed anti-MRSA therapy (vancomycin, teicoplanin, or linezolid).<\/jats:p>\n            <jats:p>The present study assessed the impact of ASP implementation by comparing six months before ASP, i.e. from 01.10.2022 to 31.03.2023 and following ASP implementation from 01.10.2023 to 31.03.2024. Hence, evaluating adherence to hospital protocol for MRSA management and antibiotic timeout process. One of the principal elements that this study focused on was to quantify the consumption of Linezolid before and after ASP implementation, which was measured utilizing the World Health Organization (WHO) standardized Daily Defined Dose (DDD) per 100 patient days. Thus, enabling evaluating the effect of reducing linezolid usage on MRSA susceptibility to Linezolid and analyzing the overall expenditure on anti-MRSA therapy. The comparative analyses were performed using Permutation Welch Two Sample T-test for the continuous measures, while Chi-squared test or Fisher\u2019s exact test were utilized for categorical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Following ASP implementation, it was found that adherence to MRSA indication and timeout process significantly increased by approximately 74.3% and 57.9%, with (<jats:italic>p<\/jats:italic> values &lt; 0.001 for both), standardized effect sizes (\u03c6) of 0.70 and 0.55, respectively, Linezolid consumption decreased by approximately 85.8% and MRSA sensitivity to Linezolid improved by 18.3%. Furthermore, a reduction of 43% in the overall cost of anti-MRSA therapy was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>It was found that implementing an ASP contributes to a substantial reduction in Linezolid consumption and preserving its efficacy by maintaining MRSA susceptibility, while improving adherence to hospital protocols and timeout process. Additionally, it reduces overall expenditures on anti-MRSA therapy. These findings highlight ASP as a viable strategy for combating antibiotic resistance, particularly in resource-limited settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-11510-4","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:04:40Z","timestamp":1758002680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of an antimicrobial stewardship program on optimizing linezolid consumption and susceptibility in intensive care unit patients with methicillin-resistance staphylococcus aureus: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Heba","family":"Swidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayada","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Tarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Sweedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"11510_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355.","journal-title":"Lancet"},{"key":"11510_CR2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic resistance threats in the united states, 2019","author":"Center for Disease Control and prevention(CDC)","year":"2019","unstructured":"Center for Disease Control and prevention(CDC). Antibiotic resistance threats in the united states, 2019. Atlanta, GA: U.S. Department of Health and Human Services; 2019."},{"key":"11510_CR3","volume-title":"The core elements of hospital antibiotic stewardship programs","author":"CDC","year":"2019","unstructured":"CDC. The core elements of hospital antibiotic stewardship programs. Atlanta,GA: US Department of Health and Human Services; 2019."},{"key":"11510_CR4","unstructured":"World Health Organization. Egypt National Action Plan For Antimicrobial Resistance 2018\u20132022. Egypt developed with support from WHO country office of Egypt; 2021."},{"key":"11510_CR5","volume-title":"Web annex: infographic in: the WHO aware (Access, watch, Reserve) antibiotic book","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Web annex: infographic in: the WHO aware (Access, watch, Reserve) antibiotic book. Geneva: World Health Organization; 2022."},{"key":"11510_CR6","doi-asserted-by":"crossref","unstructured":"Hamdy NA, Kandil NH, Amer AN, Alaa Hamdy N. Status of Antimicrobial Stewardship Implementation in Selected Egyptian Hospitals: A Cross-sectional Study. 2022.","DOI":"10.21203\/rs.3.rs-507400\/v1"},{"key":"11510_CR7","doi-asserted-by":"crossref","unstructured":"Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: A systematic review. Antimicrob Resist Infect Control. 2019;8:35.","DOI":"10.1186\/s13756-019-0471-0"},{"key":"11510_CR8","volume-title":"Antimicrobial stewardship interventions: a practical guide","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Antimicrobial stewardship interventions: a practical guide. Copenhagen, Denmark: WHO Regional Office for Europe; 2021."},{"key":"11510_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/510393","volume":"44","author":"TH Dellit","year":"2007","unstructured":"Dellit TH, Owens RC, Mcgowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious diseases society of America and the society for health epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159\u201377.","journal-title":"Clin Infect Dis"},{"key":"11510_CR10","doi-asserted-by":"crossref","unstructured":"\u00d6zger HS, Faklo\u01e7lu DM, Erbay K, Albayrak A, Hlzel K. Inapropriate use of antibiotics effective against gram positive microorganisms despite restrictive antibiotic policies in icus: A prospective observational study. BMC Infect Dis. 2020;20:289.","DOI":"10.1186\/s12879-020-05005-7"},{"key":"11510_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s11096-014-9995-9","volume":"36","author":"P Guillard","year":"2014","unstructured":"Guillard P, de La Blanchardi\u00e8re A, Cattoir V, Fischer MO, Verdon R, Saint-Lorant G. Antimicrobial stewardship and linezolid. Int J Clin Pharm. 2014;36:1059\u201368.","journal-title":"Int J Clin Pharm"},{"key":"11510_CR12","doi-asserted-by":"crossref","unstructured":"Huang LJ, Chen SJ, Hu YW, Liu CY, Wu PF, Sun SM et al. The impact of antimicrobial stewardship program designed to shorten antibiotics use on the incidence of resistant bacterial infections and mortality. Sci Rep. 2022;12:913.","DOI":"10.1038\/s41598-022-04819-6"},{"key":"11510_CR13","doi-asserted-by":"crossref","unstructured":"Azzam A, Khaled H, Mosa M, Refaey N, AlSaifi M, Elsisi S et al. Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and Vancomycin in egypt: a systematic review with meta-analysis. BMC Infect Dis. 2023;23:263.","DOI":"10.1186\/s12879-023-08202-2"},{"key":"11510_CR14","doi-asserted-by":"crossref","unstructured":"Kakkar AK, Shafiq N, Singh G, Ray P, Gautam V, Agarwal R et al. Antimicrobial stewardship programs in resource constrained environments: Understanding and addressing the need of the systems. Front Public Health. 2020;8:140.","DOI":"10.3389\/fpubh.2020.00140"},{"key":"11510_CR15","doi-asserted-by":"crossref","unstructured":"Abdelkhalek M, Abo A, Elfeky E-E, Abo Elnasr LM, Abd-Elmonsef MME. Linezolid Resistance in Tanta University Hospitals: a Cross-sectional Study. 2021.","DOI":"10.21608\/ejmm.2021.89155.1000"},{"key":"11510_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jpids\/pis054","volume":"1","author":"JG Newland","year":"2012","unstructured":"Newland JG, Stach LM, De Lurgio SA, Hedican E, Yu D, Herigon JC, et al. Impact of a Prospective-Audit-With-Feedback antimicrobial stewardship program at a children\u2019s hospital. J Pediatr Infect Dis Soc. 2012;1:179\u201386.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"11510_CR17","unstructured":"Norwegian institute of public health. definition and general consideration. 2018. https:\/\/atcddd.fhi.no\/ddd\/definition_and_general_considera\/. Accessed 23 Apr 2025."},{"key":"11510_CR18","volume-title":"GLASS manual on the management of antimicrobial consumption data global antimicrobial resistance and use surveillance system (GLASS)","author":"World health organization","year":"2020","unstructured":"World health organization. GLASS manual on the management of antimicrobial consumption data global antimicrobial resistance and use surveillance system (GLASS). Geneva: World Health Organization; 2020."},{"key":"11510_CR19","volume-title":"Antimicrobial stewardship strategy: scheduled antimicrobial reassessments (antibiotic time outs)","author":"Public Health Ontario","year":"2016","unstructured":"Public Health Ontario. Antimicrobial stewardship strategy: scheduled antimicrobial reassessments (antibiotic time outs). Toronto, ON: Queen\u2019s printer for Ontario; 2016."},{"key":"11510_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s15010-016-0913-z","volume":"44","author":"N Shafiq","year":"2016","unstructured":"Shafiq N, Praveen Kumar M, Gautam V, Negi H, Roat R, Malhotra S, et al. Antibiotic stewardship in a tertiary care hospital of a developing country: establishment of a system and its application in a unit\u2014GASP initiative. Infection. 2016;44:651\u20139.","journal-title":"Infection"},{"key":"11510_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4161\/viru.21626","volume":"4","author":"GW Chung","year":"2013","unstructured":"Chung GW, Wu JE, Yeo CL, Chan D, Hsu LY. Antimicrobial stewardship: A review of prospective audit and feedback systems and an objective evaluation of outcomes. Virulence. 2013;4:151\u20137.","journal-title":"Virulence"},{"key":"11510_CR22","doi-asserted-by":"crossref","unstructured":"Papan C, Schr\u00f6der M, Hoffmann M, Knoll H, Last K, Albrecht F et al. Combined antibiotic stewardship and infection control measures to contain the spread of linezolid-resistant Staphylococcus epidermidis in an intensive care unit. Antimicrob Resist Infect Control. 2021;10.","DOI":"10.1186\/s13756-021-00970-3"},{"key":"11510_CR23","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. 2014.","DOI":"10.1186\/1471-2288-14-135"},{"key":"11510_CR24","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1093\/jac\/dkw179","volume":"71","author":"L Garc\u00eda-Mart\u00ednez","year":"2016","unstructured":"Garc\u00eda-Mart\u00ednez L, Gracia-Ahulfinger I, MacHuca I, Cantis\u00e1n S, De La Fuente S, Natera C, et al. Impact of the PROVAUR stewardship programme on linezolid resistance in a tertiary university hospital: A before-and-after interventional study. J Antimicrob Chemother. 2016;71:2606\u201311.","journal-title":"J Antimicrob Chemother"},{"key":"11510_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/08971900221130893","volume":"37","author":"EY Wang","year":"2024","unstructured":"Wang EY, Girotto JE. Approaches to reduce use and duration of Anti-MRSA agents for antimicrobial stewardship programs: A review of recent literature. J Pharm Pract. 2024;37:448\u201366.","journal-title":"J Pharm Pract"},{"key":"11510_CR26","doi-asserted-by":"crossref","unstructured":"Ignacio Barrasa-Villar J, Aibar-Rem\u00f3n C, Prieto-Andr\u00e9s P, Mareca-Do\u00f1ate R, Moliner-Lahoz J. Clinical Infectious Diseases Impact on Morbidity, Mortality, and Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms. 2017.","DOI":"10.1093\/cid\/cix411"},{"key":"11510_CR27","doi-asserted-by":"crossref","unstructured":"Simner PJ, Hindler JA, Bhowmick T, Das S, Johnson JK, Lubers BV et al. What\u2019s new in antibiograms?? Updating CLSI M39 guidance with current trends. J Clin Microbiol. 2022;60:e02210\u201321.","DOI":"10.1128\/jcm.02210-21"},{"key":"11510_CR28","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1093\/cid\/ciw118","volume":"62","author":"TF Barlam","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, Macdougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America. Clin Infect Dis. 2016;62:e51\u201377.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11510-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:04:50Z","timestamp":1758002690000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11510-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11510"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11510-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Egyptian Institutional Review Board on August 28, 2024 (Approval No: 2-2024\/18) and was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. As the research follows a retrospective study design, the requirement for informed consent was waived by the Egyptian Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1111"}}